DR. GUTMANN: Okay. We are going to jump right into our first session.
So, yesterday we began with some of our recommendations and had a very, I thought, productive discussion of them. Today we are going to continue with them.
They clump into two big categories. One is consent to hold genome sequencing and to the possible findings and how they will be treated, and the other is oversight of them.